For more updates follow Grant Thornton Bharat on WhatsApp
The consumer and retail sector witnessed sustained investment interest as businesses strengthened category leadership, expanded portfolios and pursued differentiated growth opportunities. The Q2 2026 edition of the Consumer and Retail Dealtracker analyses key themes shaping deal activity, investment priorities and sector trends. It covers strategic acquisitions, private equity and venture capital activity, cross-border transactions and emerging areas of consumer growth.
Q2 2026 witnessed moderated deal activity, with volumes declining 34% and values decreasing 33% q-o-q with 97 deals valuing USD 981 million, as investors remained selective. Despite the slowdown, strategic acquisitions and growth stage investments continued across high-conviction consumer themes.
M&A activity softened during the quarter, with deal volumes and values falling nearly 50% q-o-q with 20 deals valuing USD 184 million, reflecting a slowdown in strategic acquisitions and portfolio consolidation activity. While domestic and outbound activity softened, inbound M&A strengthened, with deal volumes doubling to four and values rising nearly fivefold.
PE/VC investments remained resilient despite lower activity levels with 75 deals valuing USD 734 million, with volumes declining 29% and values moderating 31% q-o-q, indicating a more measured funding environment while sustaining investor interest in consumer businesses.
Public market fundraising remained subdued. While IPO values increased 13% q-o-q, QIP activity resumed after no issuances in Q1 2026, though fundraising levels remained significantly below recent peaks.
The Pharma and Healthcare Dealtracker Q3 2025 by Grant Thornton Bharat analyses India’s evolving life sciences ecosystem, highlighting a 28% surge in deal volumes and a 166% rise in values. The report explores M&A, private equity, and capital market activity shaping pharma, healthcare, and biotech growth.
The report captures sector-wise shifts, investor alignment with scalable and tech-integrated models, and emerging preferences in early-stage innovation.
The first quarter of 2025 reflected sustained investor attention in India’s healthcare and pharmaceutical sector, marked by consistent deal activity and strategic alignment with long-term growth drivers.
